An SCD patient in Bahrain received the gene-editing therapy Casgevy, marking the first time the treatment has been given outside the U.S.

Citi analyst Yigal Nochomovitz lowered the firm’s price target on Crispr Therapeutics (CRSP) to $82 from $89 and keeps a Buy rating on the ...

CRISPR Therapeutics CRSP stock rose more than 25% in the past week, thanks to the encouraging fourth-quarter 2024 results and ...

This achievement follows Bahrain’s landmark decision on 2 December 2023 to become the second country globally and the first ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...

Casgevy, a gene therapy for sickle cell disease and beta thalassemia developed with Vertex Pharmaceuticals, has had a fairly slow rollout, but its launch seems to be gaining momentum. Fifty ...

People living with sickle cell are apprehensive about a revolutionary new one-off treatment that has just been approved for use on the NHS. | ITV News Granada ...

Despite slower-than-expected Casgevy enrollment, Crispr's strong cash position and diversified drug pipeline bolster its long-term growth potential. Clinical progress includes expanding authorized ...

MANAMA, Feb. 16 (Xinhua) -- Bahrain has achieved a medical milestone by successfully treating a patient with sickle cell disease (SCD) using CRISPR-based gene-editing therapy, Casgevy, the Bahrain ...

Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...

Casgevy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, is the first licensed therapy to utilise CRISPR/Cas9 gene-editing technology, whose inventors were awarded the 2020 Nobel ...